Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will acquire all outstanding shares of VERV for $10.50 per share in cash ...

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

Eli Lilly's (LLY) $1.3B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. ... it signed a $2.5 billion deal for Scorpion Therapeutics’ experimental oncology drug.

Once closed, Verve Therapeutics will be Lilly’s third targeted M&A deal this year. In January, it signed a $2.5 billion deal for Scorpion Therapeutics’ experimental oncology drug, STX-478, a ...